Amgen (AMGN) Stock Buyback History
TTM buyback yield N/A.
AMGN
TTM buyback yield
N/A
Shareholder yield (TTM)
N/A
5Y share count change
-8.1%
TTM buyback spend
N/A
SBC coverage (TTM)
0.00x
YoY change in spend
-100.0%
5Y CAGR of spend
-100.0%
Peak year (2018)
$17.79B
Cumulative spend
$96.03B
TTM metrics calculated from the four most recent reported quarters, ending (reported ).
Key takeaways
- Diluted share count is down 8.1% over the last ~5 fiscal years — buybacks are net-shrinking the share base.
- Cash buyback spend has compounded at -100.0% per year over the latest 5-year window.
- TTM repurchases used about 0% of free cash flow remaining after dividends.
Buyback context per fiscal year
Annual repurchases alongside stock-based compensation, diluted share count and the year-over-year change — useful for SBC-coverage and dilution-offset reading at a glance.
| Year | Buybacks | SBC | Net | Shares (dil.) | YoY shares | Buyback yield |
|---|---|---|---|---|---|---|
| 2025 | $0.00 | $0.00 | $0.00 | 0.54B | 0.2% | — |
| 2024 | $200.00M | $530.00M | −$330.00M | 0.54B | 0.6% | 0.14% |
| 2023 | $0.00 | $431.00M | −$431.00M | 0.54B | -0.6% | — |
| 2022 | $6.36B | $401.00M | $5.96B | 0.54B | -5.6% | 4.53% |
| 2021 | $4.97B | $341.00M | $4.63B | 0.57B | -2.9% | 3.93% |
| 2020 | $3.49B | $330.00M | $3.16B | 0.59B | -3.1% | 2.61% |
| 2019 | $7.70B | $308.00M | $7.39B | 0.61B | -8.4% | 5.39% |
| 2018 | $17.79B | $311.00M | $17.48B | 0.67B | -9.5% | 14.39% |
| 2017 | $3.16B | $329.00M | $2.83B | 0.73B | -2.5% | 2.51% |
| 2016 | $2.96B | $311.00M | $2.65B | 0.75B | -1.6% | 2.73% |
| 2015 | $1.87B | $322.00M | $1.54B | 0.77B | -0.5% | 1.53% |
| 2014 | $138.00M | $408.00M | −$270.00M | 0.77B | 0.7% | 0.11% |
| 2013 | $832.00M | $403.00M | $429.00M | 0.77B | -2.8% | 0.97% |
| 2012 | $4.61B | $362.00M | $4.25B | 0.79B | -13.7% | 7.00% |
| 2011 | $8.31B | $341.00M | $7.97B | 0.91B | -5.5% | 16.37% |
| 2010 | $3.79B | $353.00M | $3.43B | 0.96B | -5.5% | 7.39% |
| 2009 | $3.21B | $284.00M | $2.92B | 1.02B | -5.0% | 5.77% |
| 2008 | $2.27B | $0.00 | $2.27B | 1.07B | -4.3% | 3.81% |
| 2007 | $5.10B | $0.00 | $5.10B | 1.12B | -5.6% | 10.08% |
| 2006 | $2.00B | $0.00 | $2.00B | 1.19B | -5.4% | 2.51% |
| 2005 | $4.43B | $0.00 | $4.43B | 1.26B | -4.7% | 4.67% |
| 2004 | $4.07B | $0.00 | $4.07B | 1.32B | -1.9% | 5.08% |
| 2003 | $1.80B | $0.00 | $1.80B | 1.35B | 16.7% | 2.28% |
| 2002 | $1.42B | $0.00 | $1.42B | 1.15B | 6.4% | 2.28% |
| 2001 | $737.50M | $0.00 | $737.50M | 1.08B | -0.0% | 1.25% |
| 2000 | $799.90M | $0.00 | $799.90M | 1.08B | 0.6% | — |
| 1999 | $1.02B | $0.00 | $1.02B | 1.08B | 2.0% | — |
| 1998 | $912.10M | $0.00 | $912.10M | 1.06B | -3.7% | — |
| 1997 | $737.90M | $0.00 | $737.90M | 1.10B | -2.2% | — |
| 1996 | $450.00M | $0.00 | $450.00M | 1.12B | — | — |
| 1995 | $285.70M | $0.00 | $285.70M | — | — | — |
| 1994 | $300.50M | $0.00 | $300.50M | — | — | — |
| 1993 | $207.50M | $0.00 | $207.50M | — | — | — |
| 1992 | $85.90M | $0.00 | $85.90M | — | — | — |
| 1991 | $0.00 | $0.00 | $0.00 | — | — | — |
| 1990 | $0.00 | $0.00 | $0.00 | — | — | — |
| 1989 | $0.00 | $0.00 | $0.00 | — | — | — |
| 1988 | $0.00 | $0.00 | $0.00 | — | — | — |
Cash buyback spend (USD) — annual & quarterly history
Trailing-twelve-month and per-period cash repurchases for Amgen (AMGN) from the consolidated cash flow statement (line: common stock repurchased), in USD as filed.
Cash buyback spend over time for Amgen (AMGN)
Per-period cash repurchases
Cash buyback spend annual + quarterly history for Amgen (AMGN)
| Fiscal year | Period ended | Reported | Buyback Spend | YoY | YoY change |
|---|---|---|---|---|---|
| 2025 | $0 | -100.0% | -$200.00M | ||
| 2024 | $200.00M | — | +$200.00M | ||
| 2023 | $0 | -100.0% | -$6.36B | ||
| 2022 | $6.36B | +27.8% | +$1.39B | ||
| 2021 | $4.97B | +42.7% | +$1.49B | ||
| 2020 | $3.49B | -54.7% | -$4.22B | ||
| 2019 | $7.70B | -56.7% | -$10.09B | ||
| 2018 | $17.79B | +463.1% | +$14.63B | ||
| 2017 | $3.16B | +6.6% | +$195.00M | ||
| 2016 | $2.96B | +58.8% | +$1.10B | ||
| 2015 | $1.87B | +1252.9% | +$1.73B | ||
| 2014 | $138.00M | -83.4% | -$694.00M | ||
| 2013 | $832.00M | -81.9% | -$3.77B | ||
| 2012 | $4.61B | -44.6% | -$3.71B | ||
| 2011 | $8.31B | +119.6% | +$4.53B | ||
| 2010 | $3.79B | +18.0% | +$578.00M | ||
| 2009 | $3.21B | +41.4% | +$940.00M | ||
| 2008 | $2.27B | -55.5% | -$2.83B | ||
| 2007 | $5.10B | +155.0% | +$3.10B | ||
| 2006 | $2.00B | -54.9% | -$2.43B | ||
| 2005 | $4.43B | +8.8% | +$358.00M | ||
| 2004 | $4.07B | +126.1% | +$2.27B | ||
| 2003 | $1.80B | +26.8% | +$381.00M | ||
| 2002 | $1.42B | +92.5% | +$682.50M | ||
| 2001 | $737.50M | -7.8% | -$62.40M | ||
| 2000 | $799.90M | -21.9% | -$224.80M | ||
| 1999 | $1.02B | +12.3% | +$112.60M | ||
| 1998 | $912.10M | +23.6% | +$174.20M | ||
| 1997 | $737.90M | +64.0% | +$287.90M | ||
| 1996 | $450.00M | +57.5% | +$164.30M | ||
| 1995 | $285.70M | -4.9% | -$14.80M | ||
| 1994 | $300.50M | +44.8% | +$93.00M | ||
| 1993 | $207.50M | +141.6% | +$121.60M | ||
| 1992 | $85.90M | — | +$85.90M | ||
| 1991 | $0 | — | $0 | ||
| 1990 | $0 | — | $0 | ||
| 1989 | $0 | — | $0 | ||
| 1988 | $0 | — | — |
Amgen (AMGN) most recent annual buyback spend stands at $0 (2025) – plunged 100.0% year-over-year.
Amgen buyback spend has contracted on net over the period, with a -100.0% compound annual growth rate over 2020–2025 (5 years).
Amgen buyback spend plunged from $17.79B in 2018 to $0 in 2025, a 100.0% drawdown.
$17.79B stands as the all-time-high annual buyback spend, posted in 2018, against a low of $0 during 1988.
Amgen (AMGN) sits 9th of 8 Healthcare peers we track on this metric, against a peer median of $3.55B.
Amgen Buyback Spend 2025: $0
Amgen buyback spend in 2025 was $0, plunged 100.0% below 2024.
Amgen Buyback Spend 2024: $200.00M
Amgen buyback spend in 2024 was $200.00M.
Amgen Buyback Spend 2023: $0
Amgen buyback spend in 2023 was $0, plunged 100.0% below 2022.
Amgen Buyback Spend 2022: $6.36B
Amgen buyback spend in 2022 was $6.36B, grew 27.8% from 2021.
Amgen Buyback Spend 2021: $4.97B
Amgen buyback spend in 2021 was $4.97B.
See more financial history for Amgen (AMGN).
Sector peers by buyback spend
Companies in the same sector as Amgen, ranked by their latest buyback spend.
| Company | Buyback Spend | Sector |
|---|---|---|
| Johnson & Johnson (JNJ) | $5.95B | Healthcare |
| UnitedHealth Group (UNH) | $5.54B | Healthcare |
| Merck & Co. (MRK) | $5.08B | Healthcare |
| Eli Lilly (LLY) | $4.11B | Healthcare |
| Thermo Fisher Scientific (TMO) | $3.00B | Healthcare |
| Novo Nordisk (NVO) | $1.39B | Healthcare |
| AbbVie (ABBV) | $980.00M | Healthcare |
| AstraZeneca (AZN) | $719.66M | Healthcare |
Share count history
Diluted weighted-average shares drive the EPS denominator and per-share capital-return maths. A falling diluted share count means buybacks are outpacing dilution from stock-based compensation and option exercises.
Diluted vs basic shares (annual)
Year-over-year change in diluted shares
Green is fewer shares vs the prior fiscal year (net repurchase); red is growth (dilution). The earliest year shown has no prior year to compare.
Dividend & buyback yield over time
Stacked annual yields — buyback yield (TTM cash repurchases ÷ market cap) plus dividend yield from the same fiscal-year-end key-metrics period — show how total cash return per dollar of equity has evolved.
Buybacks vs stock-based compensation
Annual cash repurchases set against stock-based compensation. Coverage above 1× means buybacks fully offset the equity dilution from SBC. TTM coverage: 0.00×.
Capital allocation mix
How Amgen splits cash returned to shareholders between dividends and buybacks, plus the headroom on free cash flow that's still available for additional repurchases.
Buybacks vs dividends (share of cash returned)
Buyback capacity (TTM)
Free cash flow minus dividends paid versus actual TTM repurchases — the headroom bar shows how much of post-dividend FCF is still being deployed elsewhere.
Headroom $3.39B (TTM FCF − TTM dividends, clamped at zero).
Data & methodology
Where do buyback, dividend and compensation figures come from?
Cash buyback spend (common stock repurchased), dividends paid and stock-based compensation come from Amgen's consolidated cash flow statements — quarterly 10-Q and annual 10-K SEC filings, in USD as reported.
How are diluted shares and yields calculated?
Diluted weighted-average share counts come from the income statement (EPS denominator). Trailing twelve-month (TTM) aggregates sum the four most recent reported quarters. Buyback and dividend yields divide TTM cash flows by market capitalisation at the latest quarter-end.
How is buyback capacity defined?
Capacity compares TTM repurchases to free cash flow after dividends: operating cash flow minus capital expenditure, minus dividends paid, versus actual buybacks over the same trailing window.
Is this investment advice?
No. Figures are for informational and educational use only. Past buybacks and dividends do not predict future returns.
Frequently asked questions
Does Amgen buy back its own stock?
Yes, Amgen (AMGN) has repurchased shares in recent periods. See the history table and charts on this page for amounts and trends.
Is Amgen diluting shareholders?
Compare stock-based compensation (SBC) to buybacks in the chart above. Net effect varies by year; see annual buyback vs SBC bars and the history table.
How has Amgen's share count changed?
Diluted weighted average shares changed by about -8.1% over roughly five fiscal years (annual income statement data).
What is Amgen's buyback spend?
Latest reported buyback spend for Amgen (AMGN) is $0 (period ending March 31, 2026).
How has Amgen buyback spend changed year-over-year?
Amgen (AMGN) buyback spend changed -100.0% year-over-year on the latest annual filing.
What is the long-term growth rate of Amgen buyback spend?
Amgen (AMGN) buyback spend compound annual growth rate is -100.0% over the most recent 5 years available.
When did Amgen buyback spend hit its highest annual value?
Amgen buyback spend reached its highest annual value of $17.79B in 2018.
What was Amgen buyback spend in 2024?
Amgen (AMGN) buyback spend in 2024 was $200.00M.
What was Amgen buyback spend in 2025?
Amgen (AMGN) buyback spend in 2025 was $0.
Explore more
AMGN Overview
Company profile, financial tools, and key metrics
AMGN Revenue Counter
Earns $1,181 every second. See per minute, hour, and day.
AMGN Earnings Counter
Earns $247.34 per second net profit. See per minute, hour, and day.
AMGN Economic Scale
Exceeds Honduras's GDP. Compare with world economies.
AMGN What If Invested
What if you had invested $1,000? See historical returns from any date.
AMGN How It Makes Money
Discover visual breakdown of $37.24B in revenue — where it comes from and where it goes.
AMGN Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
AMGN Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
AMGN Daily Price Character
Balanced · 48.1% historical win rate (green days). Streaks & record days.
AMGN Stock Split History
5 splits on record. Dates, ratios, and cumulative multiple.
AMGN Dividend Profile
Yield: 2.96%. Safety: 8/8. See full history.
AMGN Dividend Calculator
How much dividend income would $1,000 have earned? Calculate from any date.
AMGN Dividend Forecast
Project future income with DRIP, growth assumptions, and optional monthly contributions.
AMGN Dividend Capture
Historical pre-ex touch stats, gap distribution, after-tax calculator, and a backtest simulator (limit-order vs MOC exit).
AMGN Financials
Revenue, EPS, EBITDA, market cap, debt and balance sheet history with annual and quarterly data.